Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Darolutamide (ODM-201) in Patients With Androgen Receptor-positive Salivary Gland Carcinoma (Discovary Study)

NCT05694819 is registered in ClinicalTrials.gov with National Cancer Center Hospital East as lead sponsor.

NCT NCT05694819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05694819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Darolutamide (ODM-201) in Patients With Androgen Receptor-positive Salivary Gland Carcinoma (Discovary Study)
Lead sponsor
National Cancer Center Hospital East
Phase
Phase 2
Overall status
Completed
Start date
April 17, 2020
Completion date
March 23, 2026
Enrollment
57 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

salivary gland cancer